Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations Aiming to Prevent New Cancer Cases, ESMO Calls for Increased Minimum EU Excise Duty Rates on Tobacco Products in its Response to the Public... MOST POPULAR Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases September 14, 2021 Help Desk for Oncologists Treating People with a Rare Leukemia Pays... February 2, 2023 ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step... July 4, 2025 FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple... August 8, 2025 Load more HOT NEWS How the National Cancer Act Has Made a Difference in Cancer... After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms Experimental CAR T-Cell Therapy Shrinks Tumors in Children with Deadly Brain... Discovering the BRCA2 gene – 25 years on
